BRPI0418113A - composto, composição farmacêutica, e, métodos para tratar um distúrbio prostático, para tratar um distúrbio angiogênico, para tratar um distúrbio patológico, para tratar uma doença ou distúrbio neurodegenerativos, para tratar mieloma múltiplo ou leucemia, para tratar cáncer de tumores sólidos e para tratar um tumor hematológico - Google Patents

composto, composição farmacêutica, e, métodos para tratar um distúrbio prostático, para tratar um distúrbio angiogênico, para tratar um distúrbio patológico, para tratar uma doença ou distúrbio neurodegenerativos, para tratar mieloma múltiplo ou leucemia, para tratar cáncer de tumores sólidos e para tratar um tumor hematológico

Info

Publication number
BRPI0418113A
BRPI0418113A BRPI0418113-1A BRPI0418113A BRPI0418113A BR PI0418113 A BRPI0418113 A BR PI0418113A BR PI0418113 A BRPI0418113 A BR PI0418113A BR PI0418113 A BRPI0418113 A BR PI0418113A
Authority
BR
Brazil
Prior art keywords
treating
disorder
methods
compound
pharmaceutical composition
Prior art date
Application number
BRPI0418113-1A
Other languages
English (en)
Inventor
Nadine C Becknell
James L Diebold
Diane E Gingrich
Robert L Hudkins
Dandu R Reddy
Ming Tao
Theodore L Underiner
Allison L Zulli
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BRPI0418113A publication Critical patent/BRPI0418113A/pt
Publication of BRPI0418113B1 publication Critical patent/BRPI0418113B1/pt
Publication of BRPI0418113B8 publication Critical patent/BRPI0418113B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA TRATAR UM DISTúRBIO PROSTáTICO, PARA TRATAR UM DISTúRBIO ANGIOGêNICO, PARA TRATAR UM DISTúRBIO PATOLóGICO PARA TRATAR UMA DOENçA OU DISTúRBIO NEURODEGENERATIVOS, PARA TRATAR MIELOMA MúLTIPLO OU LEUCEMIA, PARA TRATAR CáNCER DE TUMORES SóLIDOS E PARA TRATAR UM TUMOR HEMATOLóGICO". A presente invenção no geral diz respeito aos pirrolocarbazóis fundidos selecionados, incluindo suas composições farmacêuticas e métodos de tratar doenças com estes. A presente invenção também é direcionada aos intermediários e processos para fabricar estes pirrolocarbazóis fundidos.
BRPI0418113A 2003-12-23 2004-12-23 composto, e, composição farmacêutica BRPI0418113B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53218203P 2003-12-23 2003-12-23
US60/532,182 2003-12-23
US11/017,947 US7169802B2 (en) 2003-12-23 2004-12-22 Fused pyrrolocarbazoles
US11/017,947 2004-12-22
PCT/US2004/043160 WO2005063763A1 (en) 2003-12-23 2004-12-23 Novel fused pyrrolocarbazoles

Publications (3)

Publication Number Publication Date
BRPI0418113A true BRPI0418113A (pt) 2007-04-17
BRPI0418113B1 BRPI0418113B1 (pt) 2020-04-14
BRPI0418113B8 BRPI0418113B8 (pt) 2021-05-25

Family

ID=34703676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418113A BRPI0418113B8 (pt) 2003-12-23 2004-12-23 composto, e, composição farmacêutica

Country Status (29)

Country Link
US (4) US7169802B2 (pt)
EP (1) EP1704148B1 (pt)
JP (1) JP5006046B2 (pt)
KR (2) KR101179372B1 (pt)
CN (1) CN1918162B (pt)
AR (1) AR047168A1 (pt)
AT (1) ATE500256T1 (pt)
AU (1) AU2004309394B2 (pt)
BR (1) BRPI0418113B8 (pt)
CA (1) CA2549627C (pt)
CR (1) CR8519A (pt)
CY (1) CY1111524T1 (pt)
DE (1) DE602004031672D1 (pt)
DK (1) DK1704148T3 (pt)
EA (1) EA012295B1 (pt)
HR (1) HRP20110373T1 (pt)
IL (1) IL176384A (pt)
IS (1) IS8519A (pt)
MA (1) MA28298A1 (pt)
MY (2) MY143373A (pt)
NO (2) NO336893B1 (pt)
NZ (1) NZ548099A (pt)
PL (1) PL1704148T3 (pt)
PT (1) PT1704148E (pt)
RS (1) RS51886B (pt)
SG (1) SG149045A1 (pt)
SI (1) SI1704148T1 (pt)
TW (1) TWI355385B (pt)
WO (1) WO2005063763A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP2064178A4 (en) * 2006-09-08 2011-10-05 Merck Canada Inc PRODRUGS OF INHIBITORS OF CATHEPSIN S
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US9061009B2 (en) * 2007-06-08 2015-06-23 University Of Massachusetts Mixed lineage kinases and metabolic disorders
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
BRPI0919564A2 (pt) 2008-10-22 2019-09-24 Genentech, Inc modulação da degeneração do axônio
WO2010059795A1 (en) * 2008-11-19 2010-05-27 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (en) * 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
ES2554623T3 (es) * 2008-12-30 2015-12-22 Arqule, Inc. Compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida
US8263610B2 (en) * 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
CN104043126A (zh) * 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
EP2571885B1 (en) * 2010-05-18 2014-11-12 Cephalon, Inc. Method for purifying a fused pyrrolocarbazole derivative
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
EP2954331B1 (en) 2013-02-11 2018-03-28 Incuron LLC Use of facilitates chromatin transcription complex (fact) in cancer
EP3049077A4 (en) * 2013-09-26 2017-02-15 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN106572992A (zh) 2014-04-06 2017-04-19 英丘伦有限责任公司 用curaxins进行组合治疗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP2000516250A (ja) 1996-08-22 2000-12-05 ブリストルーマイヤーズ スクイブ カンパニー インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
DK1325011T3 (da) * 2000-09-29 2004-08-16 Lilly Co Eli Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
US7169802B2 (en) 2007-01-30
PT1704148E (pt) 2011-05-25
WO2005063763A1 (en) 2005-07-14
PL1704148T3 (pl) 2011-07-29
EP1704148B1 (en) 2011-03-02
US20120004253A1 (en) 2012-01-05
CN1918162B (zh) 2014-05-14
EA200601217A1 (ru) 2006-12-29
HK1096096A1 (en) 2007-05-25
JP2007516293A (ja) 2007-06-21
CR8519A (es) 2007-06-06
NO20151245A1 (no) 2015-09-23
EP1704148A1 (en) 2006-09-27
EA012295B1 (ru) 2009-08-28
TW200530243A (en) 2005-09-16
AU2004309394B2 (en) 2011-04-28
DK1704148T3 (da) 2011-06-14
KR101179372B1 (ko) 2012-09-03
TWI355385B (en) 2012-01-01
NO336893B1 (no) 2015-11-23
US20050143442A1 (en) 2005-06-30
BRPI0418113B8 (pt) 2021-05-25
NO20063196L (no) 2006-09-20
DE602004031672D1 (de) 2011-04-14
KR20120066057A (ko) 2012-06-21
ATE500256T1 (de) 2011-03-15
AU2004309394A1 (en) 2005-07-14
US20060247294A1 (en) 2006-11-02
IL176384A0 (en) 2006-10-05
IL176384A (en) 2015-05-31
US7671064B2 (en) 2010-03-02
AR047168A1 (es) 2006-01-11
MY158159A (en) 2016-09-15
RS51886B (sr) 2012-02-29
CY1111524T1 (el) 2015-08-05
MY143373A (en) 2011-04-29
JP5006046B2 (ja) 2012-08-22
HRP20110373T1 (hr) 2011-06-30
NZ548099A (en) 2010-05-28
US20100152196A1 (en) 2010-06-17
CN1918162A (zh) 2007-02-21
SI1704148T1 (sl) 2011-06-30
KR20060127069A (ko) 2006-12-11
US8383813B2 (en) 2013-02-26
BRPI0418113B1 (pt) 2020-04-14
CA2549627A1 (en) 2005-07-14
MA28298A1 (fr) 2006-11-01
IS8519A (is) 2006-06-22
US8044064B2 (en) 2011-10-25
CA2549627C (en) 2012-12-11
SG149045A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0418113B8 (pt) composto, e, composição farmacêutica
BRPI0418120A (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio, uma doença ou distúrbio, e para tratar mieloma múltiplo ou leucemia
DE69842094D1 (de) Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
DE60011612D1 (de) Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
WO2003058201A3 (en) Methods for identifying marker genes for cancer
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
MA30654B1 (fr) Therapie tumorale avec anticorps anti-vegf
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
BR9701248A (pt) Novos pró-medicamentos para a terapia de tumores e distúrbios inflamatórios
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
BR0212661A (pt) Compostos de pirazolil benzenossulfamida substituìdos para o tratamento de inflamação
ATE359786T1 (de) Camptothecin derivate
BR0111140A (pt) Forma polimórfica, composição farmacêutica, métodos para o tratamento de uma doença inflamatória, de uma doença mediada por ciclooxigenase, de dor, e, processo para fabricar um polimorfo de forma v
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
BRPI0414736A (pt) 5-aril-pirimidinas como agentes anticáncer
DK1441724T3 (da) Fremgangsmåde til forögelse af endogene testosteronniveauer
ATE445842T1 (de) Nachweis spezifischer nitrierter marker
CY1110788T1 (el) Διαγονιδιακα ζωα τα οποια παρουσιαζουν σημαντικες διαταραχες σχετικες με την νοσο alzheimer
BR0116600A (pt) Método para a preparação regiosseletiva de benzo(g)quinolina-3-carbonitrilas e benzo(g)quinazolinas substituìdas
WO2004064783A3 (en) Eosinophil-derived neurotoxin as a marker for ovarian cancer
MX2024005153A (es) Compuestos y metodos dirigidos a la interleucina-34.
ATE516038T1 (de) Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2516 DE 26/03/2019 POR TER SIDO INDEVIDA.

B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed